Health Technology · Pharmaceuticals: Other · NSE: LYKALABS · data 2026-10-09

Lyka Labs Limited

Health check: Weak (2.5/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹72.65

Market cap

₹262 cr

P/E

—

P/B

—

ROE

-10.2%

ROCE

-9.9%

Debt / equity

0.53

Dividend yield

0.00%

1-year return

-25.1%

52-week high

₹100.94

52-week low

₹44.1

Operating margin

-8.1%

Growth

Revenue (last 12 months)	₹138 cr
Net profit (last 12 months)	₹-9 cr
Sales growth, 3 years (yearly)	11.8%
Profit growth, 3 years (yearly)	—

Similar companies

Amrutanjan Health Care Limited (AMRUTANJAN) · Shri Ahimsa Naturals Limited (SHRIAHIMSA) · Influx Healthtech Limited (INFLUX) · Sat Kartar Life Limited (SATKARTAR) · Natural Capsules Limited (NATCAPSUQ)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open LYKALABS in NSE Scanner →